Upadacitinib in refractory ulcerative colitis patients with high thromboembolic risk: two case reports [PDF]
Frontiers in ImmunologyUpadacitinib is a novel selective Janus kinase (JAK) inhibitor approved for adults with ulcerative colitis (UC). While caution is advised when considering upadacitinib as a treatment option for patients with an increased risk of thrombosis.
Rui Mo +3 more
doaj +2 more sources
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies [PDF]
RMD OpenIntroduction Patients with rheumatoid (RA) or psoriatic (PsA) arthritis can experience debilitating pain.Methods Post hoc analyses of phase 3, double-blind studies in patients with active disease despite treatment (SELECT-COMPARE, SELECT-PsA 1) assessed ...
Bruno Fautrel +10 more
doaj +2 more sources
REAL-WORLD EXPERIENCE WITH JANUS KINASE INHIBITORS IN EXTRAINTESTINAL MANIFESTATIONS AND INFLAMMATORY BOWEL DISEASE IN COLOMBIA: A COMPARATIVE STUDY (JAKEIM-IBD STUDY) [PDF]
Arquivos de GastroenterologiaBackground: Extraintestinal manifestations (EIMs) significantly impact patients with inflammatory bowel disease (IBD). Janus kinase inhibitors (JAKi) are emerging as a potential treatment.
Viviana PARRA-IZQUIERDO +8 more
doaj +2 more sources
Upadacitinib for psoriatic arthritis refractory to biologics : SELECT-PsA 2 [PDF]
, 2021 Background: Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying ...
Anderson, Jaclyn K. +13 more
core +1 more source
Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]
, 2020 On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P. +4 more
core +2 more sources
Upadacitinib for Patients with Rheumatoid Arthritis : A Comprehensive Review [PDF]
, 2023 Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor recently approved by the European Medicine Agency and the Food and Drug Administration for the treatment of rheumatoid arthritis (RA) at a dose of 15 mg/day.
Corominas, Hèctor +2 more
core +1 more source
Heliyon, 2023 Background: The sparsity of head-to-head trials for medications used as in atopic dermatitis (AD) treatment makes therapy options difficult. Objective: To better compare the efficacy and safety of abrocitinib and upadacitinib with dupilumab in patients ...
Qin Gao, Yanxia Zhao, Junling Zhang
doaj +1 more source
Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease [PDF]
, 2020 Background & Aims: We evaluated the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, in a randomized trial of patients with Crohn's disease (CD).
Armuzzi, Alessandro +22 more
core +2 more sources
Long‑term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real‑world Setting: An Interim Analysis Through 48 Weeks of Observation [PDF]
, 2023 Background Janus kinase (JAK) inhibitors, including upadacitinib, have been recently approved for the treatment of moderate- severe atopic dermatitis (AD) and real-world data on upadacitinib effectiveness and safety are limited.
Andrea Chiricozzi +5 more
core +1 more source
Dermatology and Therapy, 2023 Introduction Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is used to treat moderate-to-severe atopic dermatitis (AD). Acne is the most common treatment-emergent adverse event in patients with AD treated with upadacitinib.
Nobukazu Hayashi +6 more
doaj +1 more source